"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Mamie McFaddin Ward Cancer Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 16 clinical trials were completed, i.e. on average, 177.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mamie McFaddin Ward Cancer Center" #1 sponsor was "US Oncology Research" with 10 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Agennix" with 1 trials sponsored, "Biotheranostics, Inc." with 1 trials sponsored and "Calithera Biosciences, Inc" with 1 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mamie McFaddin Ward Cancer Center" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "ARMO BioSciences" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Mamie McFaddin Ward Cancer Center" are "Breast Cancer" (4 trials), "Metastatic Breast Cancer" (4 trials), "Metastatic Prostate Cancer" (2 trials), "Non Small Cell Lung Cancer" (2 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Mamie McFaddin Ward Cancer Center" in a lesser frequency.

Most popular intervention types in "Mamie McFaddin Ward Cancer Center" are "Drug" (23 trials), "Biological" (5 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "Cetuximab" (2 trials), "Nivolumab" (2 trials), "Pegilodecakin" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Mamie McFaddin Ward Cancer Center" are 17 trials for "All" genders, 6 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Mamie McFaddin Ward Cancer Center". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Mamie McFaddin Ward Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Mamie McFaddin Ward Cancer Center, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".